A straightforward guide to the basic science behind cardiovascular cell-based therapies

Heart

Volumn 100, Issue 15, 2014, Pages 1153-1157

  Goumans, Marie José ^a   Maring, Janita A ^a   Smits, Anke M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; SCLEROPROTEIN; SOMATOMEDIN C; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

BLOOD FLOW; BONE MARROW CELL; CELL DIFFERENTIATION; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; DISEASE SEVERITY; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HUMAN; MEMBRANE STEADY POTENTIAL; MESENCHYMAL STEM CELL; MONONUCLEAR CELL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; TISSUE REGENERATION; WOUND HEALING;

BASIC SCIENCE; MYOCARDIAL ISCHAEMIA AND INFARCTION (IHD);

BIOMEDICAL RESEARCH; CARDIOVASCULAR DISEASES; CELL- AND TISSUE-BASED THERAPY; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84903977671     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2014-305646     Document Type: Review

References (44)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
2. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 2008;58:88-111.
3. Frangogiannis NG. The mechanistic basis of infarct healing. Antioxid Redox Signal 2006;8:1907-39. (Pubitemid 46504897)
4. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000;101:2981-8. (Pubitemid 30415891)
5. Jeevanantham V, Butler M, Saad A, et al. Adult bone marrow cell therapy improves survival and induces long- Term improvement in cardiac parameters: A systematic review and meta- Analysis. Circulation 2012;126:551-68.
6. Karantalis V, Balkan W, Schulman IH, et al. Cell-based therapy for prevention and reversal of myocardial remodeling. Am J Physiol Heart Circ Physiol 2012;303: H256-70.
7. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701-5. (Pubitemid 32290358)
8. Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001;7:430-6. (Pubitemid 32298545)
9. Murry CE, Soonpaa MH, Reinecke H, et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004;428:664-8. (Pubitemid 38524810)
10. Balsam LB, Wagers AJ, Christensen JL, et al. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 2004;428:668-73. (Pubitemid 38524811)
11. Nygren JM, Jovinge S, Breitbach M, et al. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med 2004;10:494-501. (Pubitemid 38667908)
12. Yeghiazarians Y, Zhang Y, Prasad M, et al. Injection of bone marrow cell extract into infarcted hearts results in functional improvement comparable to intact cell therapy. Mol Ther 2009;17:1250-6.
13. Korf-Klingebiel M, Kempf T, Sauer T, et al. Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction. Eur Heart J 2008;29:2851-8.
14. Shintani Y, Fukushima S, Varela-Carver A, et al. Donor cell- Type specific paracrine effects of cell transplantation for post-infarction heart failure. J Mol Cell Cardiol 2009;47:288-95.
15. Li Y, Guo X, Xue Q, et al. Single cell gene profiling revealed heterogeneity of paracrine effects of bone marrow cells in mouse infarcted hearts. PLoS One 2013;8: e68270.
16. Loffredo FS, Steinhauser ML, Gannon J, et al. Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell 2011;8:389-98.
17. Ramkisoensing AA, Pijnappels DA, Askar SF, et al. Human embryonic and fetal mesenchymal stem cells differentiate toward three different cardiac lineages in contrast to their adult counterparts. PLoS One 2011;6:e24164.
18. Williams AR, Suncion VY, McCall F, et al. Durable scar size reduction due to allogeneic mesenchymal stem cell therapy regulates whole-chamber remodeling. J Am Heart Assoc 2013;2:e000140.
19. Tang J, Xie Q, Pan G, et al. Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with reperfusion. Eur J Cardiothorac Surg 2006;30:353-61. (Pubitemid 44051890)
20. Siegel G, Krause P, Wohrle S, et al. Bone marrow-derived human mesenchymal stem cells express cardiomyogenic proteins but do not exhibit functional cardiomyogenic differentiation potential. Stem Cells Dev 2012;21:2457-70.
21. Schinkothe T, Bloch W, Schmidt A. In vitro secreting profile of human mesenchymal stem cells. Stem Cells Dev 2008;17:199-206.
22. Timmers L, Lim SK, Hoefer IE, et al. Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. Stem Cell Res 2011;6:206-14.
23. Kasper G, Glaeser JD, Geissler S, et al. Matrix metalloprotease activity is an essential link between mechanical stimulus and mesenchymal stem cell behavior. Stem Cells 2007;25:1985-94. (Pubitemid 47258176)
24. Ohnishi S, Sumiyoshi H, Kitamura S, et al. Mesenchymal stem cells attenuate cardiac fibroblast proliferation and collagen synthesis through paracrine actions. FEBS Lett 2007;581:3961-6. (Pubitemid 47212103)
25. Mangi AA, Noiseux N, Kong D, et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003;9:1195-201. (Pubitemid 37173705)
26. Haider H, Jiang S, Idris NM, et al. IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1alpha/CXCR4 signaling to promote myocardial repair. Circ Res 2008;103:1300-8.
27. Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 2011;109:923-40.
28. Rodrigo SF, van Ramshorst J, Hoogslag GE, et al. Intramyocardial injection of autologous bone marrow-derived ex vivo expanded mesenchymal stem cells in acute myocardial infarction patients is feasible and safe up to 5 years of follow-up. J Cardiovasc Transl Res 2013;6:816-25.
29. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science 2009;324:98-102.
30. Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003;114:763-76. (Pubitemid 37186770)
31. Smits AM, Ramkisoensing AA, Atsma DE, et al. Young at heart an update on cardiac regeneration. Minerva Med 2010;101:255-70.
32. Goumans MJ, de Boer TP, Smits AM, et al. TGF-beta1 induces efficient differentiation of human cardiomyocyte progenitor cells into functional cardiomyocytes in vitro. Stem Cell Res 2007;1:138-49.
33. Smits AM, van Laake LW, den Ouden K, et al. Human cardiomyocyte progenitor cell transplantation preserves long- Term function of the infarcted mouse myocardium. Cardiovasc Res 2009;83:527-35.
34. Smith RR, Barile L, Cho HC, et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 2007;115:896-908. (Pubitemid 46294730)
35. den Haan MC, Grauss RW, Smits AM, et al. Cardiomyogenic differentiationindependent improvement of cardiac function by human cardiomyocyte progenitor cell injection in ischaemic mouse hearts. J Cell Mol Med 2012;16:1508-21.
36. van Oorschot AA, Smits AM, Pardali E, et al. Low oxygen tension positively influences cardiomyocyte progenitor cell function. J Cell Mol Med 2011;15:2723-34.
37. Tang XL, Rokosh G, Sanganalmath SK, et al. Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. Circulation 2010;121:293-305.
38. Bolli R, Tang XL, Sanganalmath SK, et al. Intracoronary delivery of autologous cardiac stem cells improves cardiac function in a porcine model of chronic ischemic cardiomyopathy. Circulation 2013;128:122-31.
39. Malliaras K, Makkar RR, Smith RR, et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol 2014;63:110-22.
40. Chugh AR, Beache GM, Loughran JH, et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: The SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation 2012;126:S54-S64.
41. Heeschen C, Lehmann R, Honold J, et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 2004;109:1615-22. (Pubitemid 38451717)
42. Kissel CK, Lehmann R, Assmus B, et al. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J Am Coll Cardiol 2007;49:2341-9. (Pubitemid 46891715)
43. Zhuo Y, Li SH, Chen MS, et al. Aging impairs the angiogenic response to ischemic injury and the activity of implanted cells: combined consequences for cell therapy in older recipients. J Thorac Cardiovasc Surg 2010;139:1286-94.
44. Sluijter JP, Verhage V, Deddens JC, et al. Microvesicles and exosomes for intracardiac communication. Cardiovasc Res 2014;102:302-11.